Change at the top at Biogen after struggles with Aduhelm
Biogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Biogen is looking for a new CEO less than a year after the launch of its Alzheimer’s drug largely fizzled.
The company said Tuesday that current CEO Michel Vounatsos will continue to lead the company until a successor is found.
Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, it was expected to quickly become a blockbuster drug that would generate billions for Biogen.
The Cambridge, Massachusetts, company has since slashed the price in half — to $28,000 a year — and Aduhelm’s rollout has been disastrous.
The federal government imposed tight Medicare coverage restrictions on the drug, which brought in $2.8 million in sales in the recently completed first quarter.
Biogen said Tuesday it booked about $275 million in charges from Aduhelm inventory write-offs in the quarter, and it would “substantially eliminate” its commercial infrastructure supporting the drug.